Pharmafile Logo

Senate drug price inquiry

market access in Japan

Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

Petauri Evidence

- PMLiVE

Democrats in the US agree plan to curb drug prices

House Democrats have added a measure to curb prescription drug costs to President Biden’s $1.85tr social safety net plan

- PMLiVE

White House unveils plans to reimport medicines from Canada

Unthinkable to previous administrations, but scepticism rife amid flurry of policy ideas

- PMLiVE

PhRMA opposed to Senate drug price control plans

But has bipartisan support and Trump backing

- PMLiVE

Another setback on pricing as Trump drops rebate plans

Follows pharma's blocking of advertising changes

- PMLiVE

Trump presses on with reference pricing plan for medicines

Proposed pilot programme to run until 2025

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Tit for tat as PBMs blame pharma for high drug prices

US Senate turns its spotlight on 'middlemen'

- PMLiVE

Gottlieb signs off with flair – and pledge of further drug price commentary

Highlights issues of insulin prices and competition

- PMLiVE

Trump budget targets rebates, out-of-pocket costs

Biotech sector welcomes end to rebates, but worries about Medicare cuts

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links